[go: up one dir, main page]

CA2488012A1 - Genes modificateurs cftr et polypeptides exprimes utiles pour traiter la mucoviscidose et techniques et produits permettant de detecter et/ou d'identifier ceux-ci - Google Patents

Genes modificateurs cftr et polypeptides exprimes utiles pour traiter la mucoviscidose et techniques et produits permettant de detecter et/ou d'identifier ceux-ci Download PDF

Info

Publication number
CA2488012A1
CA2488012A1 CA002488012A CA2488012A CA2488012A1 CA 2488012 A1 CA2488012 A1 CA 2488012A1 CA 002488012 A CA002488012 A CA 002488012A CA 2488012 A CA2488012 A CA 2488012A CA 2488012 A1 CA2488012 A1 CA 2488012A1
Authority
CA
Canada
Prior art keywords
cftr
cftr modifier
gene
benzimidazole
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002488012A
Other languages
English (en)
Inventor
Jeffrey Allen Whitsett
Bruce Jefferson Aronow
Jean Cantwell Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2488012A1 publication Critical patent/CA2488012A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

On a découvert que des gènes modificateurs CFTR, en particulier le gène Kir4.2, qu'un ou des polypeptides exprimés, ainsi que des régulateurs génétiques et polypeptidiques de ces derniers, peuvent être utilisés pour traiter la mucoviscidose (CF) ou au moins, les états (CF) que cette maladie entraîne. La présente invention concerne des techniques et des produits permettant de détecter et/ou d'identifier des gènes modificateurs CFTR, leurs polypeptides exprimés respectifs, les régulateurs génétiques de ces gènes modificateurs CFTR et les régulateurs de leurs polypeptides exprimés respectifs. Cette invention concerne aussi des compositions et des techniques qui utilisent ces gènes modificateurs CFTR, leurs polypeptides exprimés respectifs, des régulateurs génétiques de ces gènes modificateurs CFTR et/ou des régulateurs de polypeptide modificateur CFTR dans le but de traiter la mucoviscidose (CF) ou au moins, les états que cette maladie (CF) entraîne.
CA002488012A 2002-05-31 2003-05-30 Genes modificateurs cftr et polypeptides exprimes utiles pour traiter la mucoviscidose et techniques et produits permettant de detecter et/ou d'identifier ceux-ci Abandoned CA2488012A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38485602P 2002-05-31 2002-05-31
US38485502P 2002-05-31 2002-05-31
US60/384,856 2002-05-31
US60/384,855 2002-05-31
PCT/US2003/016896 WO2003102140A2 (fr) 2002-05-31 2003-05-30 Genes modificateurs cftr et polypeptides exprimes utiles pour traiter la mucoviscidose et techniques et produits permettant de detecter et/ou d'identifier ceux-ci

Publications (1)

Publication Number Publication Date
CA2488012A1 true CA2488012A1 (fr) 2003-12-11

Family

ID=29715352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002488012A Abandoned CA2488012A1 (fr) 2002-05-31 2003-05-30 Genes modificateurs cftr et polypeptides exprimes utiles pour traiter la mucoviscidose et techniques et produits permettant de detecter et/ou d'identifier ceux-ci

Country Status (6)

Country Link
EP (1) EP1513870A4 (fr)
JP (1) JP2005528449A (fr)
CN (1) CN1671734A (fr)
AU (1) AU2003238791A1 (fr)
CA (1) CA2488012A1 (fr)
WO (1) WO2003102140A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240076682A1 (en) * 2022-08-29 2024-03-07 Universita' Degli Studi Di Bari Aldo Moro Promoter of the transcription of nucleic acid sequence an its use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101392026B (zh) * 2008-10-09 2011-11-09 黄岚 用于预防和治疗纤维化类疾病以及肝癌的多肽
CA2793877A1 (fr) * 2010-03-22 2011-09-29 Esoterix Genetic Laboratories, Llc Mutations associees a la mucoviscidose
JP6049719B2 (ja) * 2011-08-05 2016-12-21 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ Ａｎｉｓｏｃｈｉｌｕｓｖｅｒｔｉｃｉｌｌａｔｕｓ由来のピマランジテルペン
WO2014058974A1 (fr) * 2012-10-10 2014-04-17 Emory University Méthodes de gestion d'inflammation au moyen d'inhibiteurs de la voie de la glycolyse
HUE042640T2 (hu) * 2013-03-14 2019-07-29 Translate Bio Inc CFTR-mRNS-készítmények, valamint kapcsolódó eljárások és alkalmazások
CN109280704A (zh) * 2018-10-12 2019-01-29 郑州大学第附属医院 Rasd1作为标志物在制备b-all诊断和预后评估试剂盒中的应用
US12220400B2 (en) * 2018-10-30 2025-02-11 Amilyfe, Llc Amino acid compositions and methods for treating cystic fibrosis
CN113604583B (zh) * 2021-08-10 2024-04-02 河南省畜牧总站 一种山羊kcnj15基因cnv标记辅助检测生长性状的方法及其专用试剂盒

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240076682A1 (en) * 2022-08-29 2024-03-07 Universita' Degli Studi Di Bari Aldo Moro Promoter of the transcription of nucleic acid sequence an its use

Also Published As

Publication number Publication date
EP1513870A2 (fr) 2005-03-16
EP1513870A4 (fr) 2006-06-07
WO2003102140A3 (fr) 2004-06-10
CN1671734A (zh) 2005-09-21
JP2005528449A (ja) 2005-09-22
AU2003238791A1 (en) 2003-12-19
WO2003102140A2 (fr) 2003-12-11

Similar Documents

Publication Publication Date Title
JP3253073B2 (ja) 嚢胞性線維症のための遺伝子治療
US5840702A (en) Cystic fibrosis treatment
JP4571695B2 (ja) 疾患関連タンパク質
Drumm et al. Molecular biology of cystic fibrosis
Yanagi et al. Distinct functions of photoreceptor cell–specific nuclear receptor, thyroid hormone receptor β2 and crx in cone photoreceptor development
WO2002064790A2 (fr) Proteine jfy induisant l'apoptose rapide
CA2488012A1 (fr) Genes modificateurs cftr et polypeptides exprimes utiles pour traiter la mucoviscidose et techniques et produits permettant de detecter et/ou d'identifier ceux-ci
Roomans Pharmacological approaches to correcting the ion transport defect in cystic fibrosis
JP7486497B2 (ja) 上皮または内皮バリア機能の改善
Schwiebert et al. Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein
US20060078558A1 (en) Diagnosis, prognosis and treatment of pulmonary diseases
CA2438571A1 (fr) Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines
US6440672B1 (en) Compositions and methods for the inhibition of MUC-5 mucin gene expression
US5688677A (en) Deoxyribonucleic acids containing inactivated hormone responsive elements
US20060014940A1 (en) Cloning and characterization of slc26a6, slc26a1, and slc26a2 anion exchangers
Masuda et al. The transcription factor GTF2IRD1 regulates the topology and function of photoreceptors by modulating photoreceptor gene expression across the retina
US20050158747A1 (en) CFTR modifier genes and expressed polypeptides useful in treating cystic fibrosis and methods and products for detecting and/or identifying same
MacVinish et al. Chloride secretion in the trachea of null cystic fibrosis mice: the effects of transfection with pTrial10‐CFTR2.
US20070036810A1 (en) Cyclic amp response element activator proteins and uses related thereto
JP2001514521A (ja) タイプ１偽性低アルドステロン症等の不完全イオン輸送に由来する病理状態の診断および治療方法
Sawczak et al. Novel approaches for potential therapy of cystic fibrosis
WO2009122748A1 (fr) Agent thérapeutique pour des maladies respiratoires ou des maladies allergiques
JP2002512041A (ja) 緑内障および前眼部形成不全の診断および予後判定のためのｆｒｅａｃ３遺伝子における新規変異
JP2007505617A (ja) 受容体
Sangiuolo et al. Toward the pharmacogenomics of cystic fibrosis–an update

Legal Events

Date Code Title Description
FZDE Dead